To view or add a comment, sign in How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA Open Access Nephrology Dialysis Transplantation, Volume 40, Issue 10, October 2025, Pages 19771988, Published: 13 May 2025 The interrelated pandemics of obesity and type 2 diabetes mellitus (T2DM) are fuelling an increase in the prevalence of chronic kidney disease (CKD), which amplifies the risk of cardiovascular events and may progress to end-stage kidney disease (ESKD)
Yes, you need a prescription to start GLP-1 medication
Available from: Mallick H, Franzosa EA, Mclver LJ, Banerjee S, Sirota-Madi A, Kostic AD, et al
Published March 5, 2024
This gel is perfect for those who prefer a topical application for efficient absorption and targeted results, making it a valuable addition to any fitness or weight loss regimen